LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. - Dataset (ID:20248)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
Hs 578T | Ruxolitinib | 10 | uM | LJP5 | 72 | hr | 929 | 2421 | 3237 | 0.7481 | 0.7023 |
Hs 578T | Momelotinib | 0.04 | uM | LJP5 | 72 | hr | 929 | 2939 | 3237 | 0.9080 | 0.8954 |
Hs 578T | Momelotinib | 0.12 | uM | LJP5 | 72 | hr | 929 | 2752 | 3237 | 0.8503 | 0.8277 |
Hs 578T | Momelotinib | 0.37 | uM | LJP5 | 72 | hr | 929 | 2528 | 3237 | 0.7811 | 0.7437 |
Hs 578T | Momelotinib | 1.11 | uM | LJP5 | 72 | hr | 929 | 2307 | 3237 | 0.7126 | 0.6567 |
Hs 578T | Momelotinib | 3.33 | uM | LJP5 | 72 | hr | 929 | 1915 | 3237 | 0.5915 | 0.4937 |
Hs 578T | Momelotinib | 10 | uM | LJP5 | 72 | hr | 929 | 1302 | 3237 | 0.4025 | 0.2062 |
Hs 578T | Fedratinib | 0.04 | uM | LJP5 | 72 | hr | 929 | 3318 | 3237 | 1.0248 | 1.0269 |
Hs 578T | Fedratinib | 0.12 | uM | LJP5 | 72 | hr | 929 | 3223 | 3237 | 0.9956 | 0.9948 |
Hs 578T | Fedratinib | 0.37 | uM | LJP5 | 72 | hr | 929 | 2959 | 3237 | 0.9141 | 0.9024 |
Hs 578T | Fedratinib | 1.11 | uM | LJP5 | 72 | hr | 929 | 2462 | 3237 | 0.7606 | 0.7180 |
Hs 578T | Fedratinib | 3.33 | uM | LJP5 | 72 | hr | 929 | 1581 | 3237 | 0.4886 | 0.3434 |
Hs 578T | Fedratinib | 10 | uM | LJP5 | 72 | hr | 929 | 921 | 3237 | 0.2846 | -0.0050 |
Hs 578T | Trametinib | 0.04 | uM | LJP5 | 72 | hr | 929 | 1525 | 3237 | 0.4713 | 0.3168 |
Hs 578T | Trametinib | 0.12 | uM | LJP5 | 72 | hr | 929 | 1458 | 3237 | 0.4507 | 0.2846 |
Hs 578T | Trametinib | 0.37 | uM | LJP5 | 72 | hr | 929 | 1485 | 3237 | 0.4587 | 0.2972 |
Hs 578T | Trametinib | 1.11 | uM | LJP5 | 72 | hr | 929 | 1464 | 3237 | 0.4525 | 0.2875 |
Hs 578T | Trametinib | 3.33 | uM | LJP5 | 72 | hr | 929 | 1419 | 3237 | 0.4384 | 0.2651 |
Hs 578T | Trametinib | 10 | uM | LJP5 | 72 | hr | 929 | 1497 | 3237 | 0.4628 | 0.3036 |
Hs 578T | Omipalisib | 0.04 | uM | LJP6 | 72 | hr | 929 | 1409 | 3216 | 0.4381 | 0.2610 |
Hs 578T | Omipalisib | 0.12 | uM | LJP6 | 72 | hr | 929 | 1291 | 3216 | 0.4016 | 0.2017 |
Hs 578T | Omipalisib | 0.37 | uM | LJP6 | 72 | hr | 929 | 1158 | 3216 | 0.3597 | 0.1287 |
Hs 578T | Omipalisib | 1.11 | uM | LJP6 | 72 | hr | 929 | 1005 | 3216 | 0.3125 | 0.0445 |
Hs 578T | Omipalisib | 3.33 | uM | LJP6 | 72 | hr | 929 | 940 | 3216 | 0.2925 | 0.0068 |
Hs 578T | Omipalisib | 10 | uM | LJP6 | 72 | hr | 929 | 862 | 3216 | 0.2678 | -0.0437 |